Milestone Pharmaceuticals (NASDAQ:MIST) Coverage Initiated at Wells Fargo & Company

Key Points

• Wells Fargo & Company initiated coverage on Milestone Pharmaceuticals with an "overweight" rating and set a price target of $4.00, indicating a potential upside of 133.92%.
• HC Wainwright upgraded the stock to a "buy" rating with a $5.00 price target, while the consensus rating remains at "Hold" with an average price target of $4.50.
• Milestone Pharmaceuticals' current stock price is $1.71, with a recent quarterly earnings report showing a loss of ($0.20) EPS, missing analysts' estimates.

Stock analysts at Wells Fargo & Company started coverage on shares of Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) in a note issued to investors on Thursday,Benzinga reports. The brokerage set an "overweight" rating and a $4.00 price target on the stock. Wells Fargo & Company's price objective suggests a potential upside of 133.92% from the stock's current price.

Separately, HC Wainwright upgraded Milestone Pharmaceuticals to a "buy" rating and set a $5.00 price target for the company in a report on Thursday, June 5th. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, Milestone Pharmaceuticals has a consensus rating of "Hold" and an average price target of $4.50.

Milestone Pharmaceuticals Stock Down 0.6%

MIST opened at $1.71 on Thursday. The firm has a 50 day moving average price of $1.70 and a 200 day moving average price of $1.55. The company has a market cap of $145.33 million, a PE ratio of -2.04 and a beta of 0.60. Milestone Pharmaceuticals has a 1 year low of $0.63 and a 1 year high of $2.75. The company has a debt-to-equity ratio of 4.06, a quick ratio of 4.97 and a current ratio of 4.97.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02). Sell-side analysts expect that Milestone Pharmaceuticals will post -0.62 earnings per share for the current year.

Institutional Trading of Milestone Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Northern Trust Corp lifted its stake in Milestone Pharmaceuticals by 112.6% during the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company's stock worth $137,000 after purchasing an additional 30,772 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in Milestone Pharmaceuticals during the fourth quarter worth $73,000. Toronto Dominion Bank bought a new position in Milestone Pharmaceuticals during the fourth quarter worth $1,770,000. XTX Topco Ltd increased its position in Milestone Pharmaceuticals by 52.7% in the first quarter. XTX Topco Ltd now owns 52,004 shares of the company's stock worth $42,000 after buying an additional 17,950 shares during the period. Finally, Walleye Capital LLC acquired a new stake in Milestone Pharmaceuticals in the first quarter worth $74,000. Institutional investors and hedge funds own 86.18% of the company's stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.